Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tolerability study of ciclopirox nail product versus placebo and Mycoster in mild to moderate onychomycosis
2005-005905-51Phase 2Completed
- Sponsor
- Stiefel Laboratories
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ciclopirox in onychomycosis (3 arms), sponsored by Stiefel Laboratories. Primary endpoints: Equivalent tolerance parameters to Mycoster and placebo, Burning assessment and 4 more. Started Jan 2006; status: completed.
02
Drugs
ciclopirox
03
Conditions
onychomycosis
Beyond the preview
Go deeper on 2005-005905-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005905-51.